Blockade of cannabinoid CB receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy.

Fiche publication

Date publication

juillet 2025

Journal

British journal of pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno

Tous les auteurs :
Pointeau O, Ba AI, Geissler A, Barbosa R, Basu A, Muhammad A, Nivot M, Loriot M, Leemput J, Passilly-Degrace P, Causse S, Demizieux L, François H, Vergès B, Duan J, Gaucher G, Harvey M, Degrace P, Crater G, Cinar R, Jourdan T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40650347

Résumé

Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose co-transporter 2 (SGLT2) inhibitors. The cannabinoid CB receptor is a potential therapeutic target. We explored combining CB receptor inverse agonism and SGLT2 inhibition for treating DN, to offer better reno-protection.